GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
5 Phases
Drug Approvals
126
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
Clinical Trials
Distribution across different clinical trial phases (3324 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
- Conditions
- Influenza, Human
- Interventions
- Biological: Flu mRNA (Formulation A)Biological: Flu mRNA (Formulation B)Combination Product: Comparator 2Combination Product: Comparator 1Combination Product: Comparator 3
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 770
- Registration Number
- NCT07121192
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
- Conditions
- Neoplasms, Endometrial
- Interventions
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT07108270
A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
- Conditions
- Pneumonia, Bacterial
- Interventions
- Biological: Pn-MAPS30plusCombination Product: PCV20
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT07105722
- Locations
- 🇦🇺
GSK Investigational Site, East Melbourne, Victoria, Australia
🇦🇺GSK Investigational site, Bayswater, Victoria, Australia
Open-label Extension Study in Participants With Early Alzheimer's Disease
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 226
- Registration Number
- NCT07105709
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT07099898
- Locations
- 🇯🇵
GSK Investigational Site, Fukuoka, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 711
- Next
News
Invivyd Raises $57.5 Million to Advance Monoclonal Antibody Pipeline Targeting RSV, Measles, and Long COVID
Invivyd completed a $57.5 million public offering in August 2025 to accelerate development of monoclonal antibody candidates for respiratory syncytial virus, measles, and Long COVID treatments.
Dynavax's Z-1018 Shingles Vaccine Matches GSK's Shingrix Efficacy with Superior Tolerability in Phase I/II Trial
Dynavax's investigational shingles vaccine Z-1018 demonstrated comparable immune responses to GSK's Shingrix, achieving a 100% humoral vaccine response rate versus 96.9% for Shingrix in adults aged 50-69 years.
Sitryx Regains Rights to First-in-Class Itaconate Mimetic SYX-1042 from Lilly After Successful Phase 1 Trial
Sitryx Therapeutics has regained rights to SYX-1042, an oral itaconate mimetic with first-in-class potential for chronic autoimmune and inflammatory diseases, from Eli Lilly following strategic portfolio reprioritization.
GSK Secures $370 Million Settlement and Future Royalties in CureVac-BioNTech mRNA Patent Dispute
GSK will receive $370 million upfront from CureVac following a patent settlement involving BioNTech and Pfizer over mRNA vaccine technology, with $320 million paid in cash.
RIPK1 Inhibitor Pipeline Shows Promise Despite Sanofi Setback in Multiple Sclerosis
Over 10 companies are developing 12+ RIPK1 inhibitor therapies targeting inflammatory and neurodegenerative diseases, with key players including Sanofi, Rigel Pharmaceuticals, and GenFleet Therapeutics advancing promising candidates.
BioCryst Names Charlie Gayer as New CEO Following Jon Stonehouse's Retirement Announcement
BioCryst Pharmaceuticals announced that CEO Jon Stonehouse will retire on December 31, 2025, with current Chief Commercial Officer Charlie Gayer set to succeed him as president in August and CEO in January 2026.
Osteosarcoma Market Poised for Significant Growth Through 2034 as Novel Therapies Enter Pipeline
The osteosarcoma market in the 7MM is expected to grow significantly by 2034, driven by extensive R&D activities and the entry of novel therapies including OST-HER2, Naxitamab 15-096, and HALMB-0168.
GSK's TIM-3 Inhibitor Cobolimab Fails Phase III Trial in Advanced Lung Cancer
GSK's anti-TIM-3 monoclonal antibody cobolimab failed to improve overall survival in the Phase III COSTAR trial for advanced non-small cell lung cancer patients previously treated with immunotherapy.
GSK Secures $12.5 Billion Deal with Hengrui for COPD Drug and 11 Additional Programs
GSK has entered into agreements with Chinese pharmaceutical company Hengrui worth up to $12.5 billion for exclusive global rights to develop 12 innovative medicines, including a potential best-in-class COPD treatment.
GSK Advances Dostarlimab in Phase 3 Colon Cancer Trial and Phase 2 Endometrial Cancer Study
GSK is conducting a Phase 3 randomized trial evaluating perioperative dostarlimab monotherapy versus standard of care in patients with untreated T4N0 or Stage III dMMR/MSI-H resectable colon cancer.